Keyphrases
Family Members
100%
Cell Growth
100%
Prostaglandin F2α
100%
Hepatocellular Carcinoma Cells
100%
Aldo-keto Reductase
100%
AKR1C3
100%
Hepatocellular Carcinoma
55%
PTGFR
44%
Knockdown
33%
Huh7 Cells
33%
Indomethacin
33%
Hepatocellular Carcinoma Patients
22%
Leading Causes of Death
11%
Poor Prognosis
11%
Lipid Metabolism
11%
Tumor
11%
Poor Response
11%
Gene Expression
11%
In Vitro Assay
11%
Path Analysis
11%
Downstream Target Genes
11%
Gene Expression Profile
11%
Public Database
11%
Early Disease
11%
Colony Formation
11%
New Drug Targets
11%
Current Therapies
11%
After Surgery
11%
Tumor Growth in Vivo
11%
Sorafenib
11%
Normal Adjacent Tissue
11%
Hepatocellular Carcinoma Tissues
11%
Response to Chemotherapy
11%
AKR1C3 Inhibitors
11%
Medicine and Dentistry
Carcinoma Cell
100%
Cell Growth
100%
Hepatocellular Carcinoma
100%
Prostaglandin F2
100%
Aldo Keto Reductase
100%
Indometacin
33%
Disease
11%
Recurrent Disease
11%
In Vitro
11%
Upregulation
11%
Gene Expression
11%
Neoplasm
11%
Tumor Progression
11%
Receptor
11%
Lipid Metabolism
11%
Colony Formation
11%
Supplementation
11%
Hepatocellular Carcinoma Cell Line
11%
Sorafenib
11%
Chemotherapy
11%
Immunology and Microbiology
Cell Growth
100%
Carcinoma Cell
100%
Prostaglandin F2
100%
Prostaglandin F2 Alpha
100%
Gene Expression
20%
Upregulation
20%
Lipid Metabolism
20%
Colony Formation
20%
Hepatocellular Carcinoma Cell Line
20%
Sorafenib
20%
Biochemistry, Genetics and Molecular Biology
Cell Growth
100%
Aldo-Keto Reductase
100%
AKR1C3
100%
Prostaglandin
100%
Prostaglandin F2alpha
50%
Lipid Metabolism
10%
Upregulation
10%
Gene Expression
10%
Tumor Progression
10%
Colony Formation
10%
Sorafenib
10%
Neuroscience
Cell Growth
100%
Prostaglandin F2
100%
Indometacin
60%
Cell Line
20%
In Vivo
20%
In Vitro
20%
Gene Expression
20%
Metabolic Pathway
20%
Sorafenib
20%
Colony Formation
20%
Receptor
20%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Prostaglandin F2
100%
Aldo Keto Reductase
100%
Indometacin
30%
Disease
10%
Recurrent Disease
10%
Neoplasm
10%
Receptor
10%
Chemotherapy
10%
Tumor Growth
10%
Sorafenib
10%